Neomatrix secures a 1 million non-dilutive grant from Lazio Innova.
21 November 2023–
Neomatrix secures a 1 million non-dilutive grant from Lazio Innova.
The main objectives of the project are two:
Characterizing vaccines based on synthetic DNA in order to produce the data necessary for EMA authorization for the phase I-II clinical trial. The studies will be divided into basic studies such as the analysis of the quality and quantity of immune responses induced by synthetic DNA compared to that induced by classic plasmid DNA and their antitumor effects. While the regulatory studies will be carried out in a GLP environment in collaboration with external CROs. These studies will be the subject of the documents (IMPD and IB) necessary to obtain EMA authorization for the phase I-II clinical trial.
Evaluation of the feasibility in the clinical context of the vaccine generation process using liquid biopsy. This objective is actually twofold, it concerns the feasibility of the process in the real world of the clinic and it plans to improve the precision of the vaccine by incorporating the information of the liquid biopsy.
The project will be carried out in a regime of effective collaboration between Neomatrix, Sapienza S. Andrea University and IRCCS Istituto Nazionale Tumori Regina Elena.